| Primary |
| Schizophrenia, Paranoid Type |
25.0% |
| Blood Pressure Management |
10.0% |
| Urinary Tract Infection |
10.0% |
| Cellulitis |
5.0% |
| Citrobacter Infection |
5.0% |
| Constipation |
5.0% |
| Dementia Alzheimer's Type |
5.0% |
| Gastrooesophageal Reflux Disease |
5.0% |
| Hiv Infection |
5.0% |
| Infection |
5.0% |
| Nocardiosis |
5.0% |
| Pneumocystis Jirovecii Pneumonia |
5.0% |
| Pulmonary Embolism |
5.0% |
| Staphylococcal Infection |
5.0% |
|
| Hallucinations, Mixed |
11.1% |
| Incorrect Route Of Drug Administration |
11.1% |
| Pallor |
11.1% |
| Purpura |
11.1% |
| Respiratory Disorder |
11.1% |
| Skin Lesion |
11.1% |
| Toxicity To Various Agents |
11.1% |
| Unresponsive To Stimuli |
11.1% |
| Urinary Tract Infection |
11.1% |
|
| Secondary |
| Hiv Infection |
36.4% |
| Product Used For Unknown Indication |
14.4% |
| Drug Use For Unknown Indication |
9.6% |
| Tuberculosis |
6.0% |
| Prophylaxis |
4.6% |
| Hiv Test Positive |
3.8% |
| Retroperitoneal Abscess |
3.7% |
| Pneumocystis Jiroveci Infection |
3.0% |
| Diffuse Large B-cell Lymphoma |
2.5% |
| Burkitt's Lymphoma |
2.3% |
| Chronic Lymphocytic Leukaemia |
2.2% |
| Immunosuppression |
2.2% |
| Antifungal Prophylaxis |
1.6% |
| Pneumocystis Jiroveci Pneumonia |
1.4% |
| Human Immunodeficiency Virus Transmission |
1.1% |
| Infection Prophylaxis |
1.1% |
| Rhodococcus Infection |
1.1% |
| Antiretroviral Therapy |
1.0% |
| Escherichia Infection |
1.0% |
| Respiratory Disorder |
1.0% |
|
| Vomiting |
15.2% |
| Pyrexia |
9.8% |
| Urogenital Disorder |
9.8% |
| Renal Failure Acute |
6.5% |
| Gastritis |
5.4% |
| Renal Impairment |
5.4% |
| Weight Decreased |
5.4% |
| Drug Exposure During Pregnancy |
4.3% |
| Rash Papular |
4.3% |
| Vanishing Bile Duct Syndrome |
4.3% |
| Hepatotoxicity |
3.3% |
| Liver Disorder |
3.3% |
| Pregnancy |
3.3% |
| Rhodococcus Infection |
3.3% |
| Sepsis |
3.3% |
| Spinal Compression Fracture |
3.3% |
| Toxicity To Various Agents |
3.3% |
| Angioedema |
2.2% |
| Hypersensitivity |
2.2% |
| Multi-organ Failure |
2.2% |
|
| Concomitant |
| Hiv Infection |
26.7% |
| Product Used For Unknown Indication |
14.9% |
| Prophylaxis |
11.4% |
| Drug Use For Unknown Indication |
10.8% |
| Diffuse Large B-cell Lymphoma |
8.2% |
| Chronic Lymphocytic Leukaemia |
7.9% |
| Antifungal Prophylaxis |
3.2% |
| Infection Prophylaxis |
2.3% |
| Tuberculosis |
1.6% |
| Plasma Cell Myeloma |
1.6% |
| Premedication |
1.6% |
| Immunosuppression |
1.4% |
| Hypertension |
1.3% |
| Immunosuppressant Drug Therapy |
1.3% |
| Antibiotic Prophylaxis |
1.0% |
| Bone Marrow Conditioning Regimen |
1.0% |
| Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis |
1.0% |
| Prophylaxis Against Graft Versus Host Disease |
1.0% |
| Diabetes Mellitus |
0.9% |
| Graft Versus Host Disease |
0.9% |
|
| Pyrexia |
14.2% |
| Vomiting |
13.8% |
| Death |
8.4% |
| Renal Failure Acute |
7.5% |
| Thrombocytopenia |
5.9% |
| Weight Decreased |
5.9% |
| Metabolic Acidosis |
4.2% |
| Sepsis |
4.2% |
| Urinary Tract Infection |
4.2% |
| Pneumonia |
3.8% |
| Tachycardia |
3.8% |
| Tuberculosis |
3.8% |
| Renal Failure |
2.9% |
| Toxic Epidermal Necrolysis |
2.9% |
| Pulmonary Embolism |
2.5% |
| Pulmonary Tuberculosis |
2.5% |
| Renal Impairment |
2.5% |
| Septic Shock |
2.5% |
| Urosepsis |
2.5% |
| Cardiac Failure Congestive |
2.1% |
|
| Interacting |
| Encephalitis |
18.2% |
| Major Depression |
18.2% |
| Oropharyngeal Discomfort |
18.2% |
| Pituitary Tumour Benign |
18.2% |
| Pneumocystis Jirovecii Infection |
18.2% |
| Cystitis |
9.1% |
|
| Drug Interaction |
66.7% |
| Tremor |
33.3% |
|
